- Home
- IPHA vs GCTS Comparison
IPHA vs GCTS Comparison
Compare IPHA & GCTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- GCTS
- Stock Information
- Founded
- IPHA 1999
- GCTS 1998
- Country
- IPHA France
- GCTS United States
- Employees
- IPHA N/A
- GCTS N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- GCTS Blank Checks
- Sector
- IPHA Health Care
- GCTS Finance
- Exchange
- IPHA Nasdaq
- GCTS Nasdaq
- Market Cap
- IPHA 150.9M
- GCTS 118.9M
- IPO Year
- IPHA 2019
- GCTS N/A
- Fundamental
- Price
- IPHA $1.95
- GCTS $2.11
- Analyst Decision
- IPHA Strong Buy
- GCTS Strong Buy
- Analyst Count
- IPHA 1
- GCTS 1
- Target Price
- IPHA $11.50
- GCTS $5.00
- AVG Volume (30 Days)
- IPHA 50.9K
- GCTS 114.6K
- Earning Date
- IPHA 03-20-2025
- GCTS 11-14-2024
- Dividend Yield
- IPHA N/A
- GCTS N/A
- EPS Growth
- IPHA N/A
- GCTS N/A
- EPS
- IPHA N/A
- GCTS N/A
- Revenue
- IPHA $36,202,722.00
- GCTS $11,532,000.00
- Revenue This Year
- IPHA N/A
- GCTS N/A
- Revenue Next Year
- IPHA $101.65
- GCTS $459.37
- P/E Ratio
- IPHA N/A
- GCTS N/A
- Revenue Growth
- IPHA N/A
- GCTS N/A
- 52 Week Low
- IPHA $1.29
- GCTS $1.98
- 52 Week High
- IPHA $3.51
- GCTS $56.00
- Technical
- Relative Strength Index (RSI)
- IPHA 56.50
- GCTS 37.32
- Support Level
- IPHA $1.72
- GCTS $1.98
- Resistance Level
- IPHA $1.92
- GCTS $2.47
- Average True Range (ATR)
- IPHA 0.11
- GCTS 0.13
- MACD
- IPHA 0.02
- GCTS -0.04
- Stochastic Oscillator
- IPHA 89.74
- GCTS 21.19
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.